Introduction {#s1}
============

Macrophages are widely distributed throughout the tissues and display a huge functional heterogeneity. They can acquire pro- or anti-inflammatory functions depending on the surrounding cytokines and tissue microenvironment.

Macrophages have been classified according to a linear scale, on which M1 macrophages represent one extreme and M2 macrophages represent the other.

Macrophage polarization is plastic and reversible. While M1 polarization takes place at the initial stages of the inflammatory response, M2 polarization is predominant during resolution of inflammation. The sequential occurrence of both polarization states is an absolute requirement for the appropriate termination of inflammatory responses, as well as for adequate tissue repair after injury, and alterations in the shift between macrophage polarization states result in chronic inflammatory pathologies, autoimmune diseases, and even metabolic disorders ([@B46]; [@B57]; [@B25]).

A main function described for macrophages is their capacity to differentiate between benign and harmful microorganisms through a pathogen-associated molecular pattern ([@B45]). When they encounter a virus or bacteria, they engulf and destroy it. However, some pathogens subvert this process and instead live inside the macrophage. This provides an environment in which the pathogen is hidden from the immune system and allows it to replicate. Diseases with this type of behavior include tuberculosis (caused by *Mycobacterium* tuberculosis) and leishmaniasis (caused by *Leishmania* species) ([@B13]; [@B58]). In order to minimize the possibility of becoming the host of an intracellular bacteria, macrophages have evolved defense mechanisms such as induction of nitric oxide and reactive oxygen intermediates, which are toxic to microbes, restrict the microbe's nutrient supply, and induce autophagy ([@B69]).

Another dimension described as essential for macrophage polarization is their metabolic profile ([@B23]). Briefly, the metabolism of M1 macrophages is characterized by enhanced glycolysis, flux through the pentose phosphate pathway (PPP), and a truncated TCA cycle, leading to the accumulation of succinate and citrate. Furthermore, the metabolic profile of M2 macrophages is defined by oxidative phosphorylation (OXPHOS), enhanced fatty acid oxidation (FAO) pathway, and a decreased glycolysis and PPP ([@B42]; [@B24]).

Macrophage polarization occurs both in physiological conditions and in pathology. In fact, these polarization stages are considered a key determinant of disease development and/or regression ([@B63]). Therefore, dissection of the molecular basis of functional macrophage subtypes should allow the identification of molecules, signaling pathways, and metabolic routes which ultimately determine the acquisition of macrophage effector functions under homeostatic and pathological conditions.

Likewise, anti-inflammatory therapies targeting macrophages by specific ablation have been used since a long time ago, displaying relevant efficacy in rheumatoid arthritis (RA), atherosclerosis, vascular injury, and cancer. However, in some cases, significant depletion of macrophages has been associated with immunosuppression, infection, and reduced wound healing ([@B48]). Thus, it seems reasonable that the next generation of macrophage-based therapies will aim to repolarize macrophages instead of eliminating them. That is the case of several tumor-associated macrophage (TAM)-targeted therapies that include inhibiting macrophage effector functions or reprogramming towards an anti-tumorigenic phenotype, with varying degrees of efficacy ([@B53]).

In this review, we will focus on specific macrophage populations, aiming to describe their biology and identify potential therapeutic targets useful in the treatment of highly prevalent pathologies such as cancer, RA, and osteoporosis.

Osteomacs, a Novel Therapeutic Target in Osteoporosis {#s2}
=====================================================

Osteoporosis is a chronic bone disease characterized by an increased risk of fracture due to the degradation of bone tissue (resorption) by overactivated monocyte-derived osteoclasts, being a leading cause of mortality in the elderly ([@B18]). Bone contains different monocyte-derived populations that perform critical functions in skeletal homeostasis ([@B64]), including resorption by osteoclasts and regulation of osteoclast actions by cytokine-secreting macrophages. Even though bone anti-resorptive therapies target osteoclasts, other monocyte-derived subpopulations, including osteal macrophages (also named osteomacs), have recently been pointed to play a key role in bone homeostasis ([@B64]).

Osteomacs are a population of osteoblast-supportive resident macrophages distributed within bone surfaces that regulate osteoblast-dependent matrix mineralization *in vitro* ([@B14]). *In vivo*, macrophage ablation in a MaFIA model (macrophage Fas-induced apoptosis transgenic mice, which have an inducible Fas apoptotic system driven by the mouse Csf1 receptor promoter) caused an osteopenic (low bone mass) phenotype with the osteoclastic cell number/activity unchanged, indicating that bone mass reduction was due to a decrease in macrophage-dependent bone formation ([@B66]).

Different approaches to potentiate macrophage osteogenic actions have been suggested to ameliorate osteoporosis, including those of immunomodulation. Interleukin-4 treatment of M1-polarized macrophage and osteoblast co-cultures showed enhanced osteogenesis by inducing macrophage phenotype shift to M2 ([@B40]). Similarly, clodronate liposome administration causes high bone mass associated with an increase of M2 osteomacs in a mouse model ([@B66]). In addition, parathormone (PTH), one of the current therapies to achieving bone formation ([@B26]), is also related to macrophage modulation in bone ([@B14]; [@B36]; [@B66]). In the MaFIA model, PTH treatment did not induce bone formation, whereas PTH treatment in control mice increased macrophage presence in bone ([@B14]). Another model that allows a transient ablation of efferocytic cells (phagocytic macrophages) by clodronate liposome administration showed a greater effect of PTH in bone mass ([@B66]). This effect was explained by the fact that, after transient macrophage depletion, a rebound of CD68^+^ M2-like macrophages occurs, increasing the secretion of osteogenic factors that might potentiate PTH bone formation ([@B66]). Based on these evidences, development of therapeutic agents that potentiate M2 macrophage populations in bone might be useful to improve osteoporosis clinical outcome.

Regarding macrophage modulation of bone fracture regeneration, an osteomac--osteoblast association has also been observed in a model of intramembranous fracture healing ([@B2]) and during endochondral ossification in a model of bone injury ([@B3]). In fact, osteomacs are distributed throughout the bone injury sites in the different stages of bone healing ([@B2]). In this regard, a pivotal role in collagen deposition and matrix mineralization during intramembranous bone healing was observed in CSF-1-activated osteomacs ([@B2]). Interestingly, preclinical studies show that CSF-1 specifically increases injury-associated osteomacs, but not inflammatory macrophages or osteoclasts, enhancing bone healing ([@B62]; [@B2]; [@B29]; [@B55]). These data suggest the potential key role of CSF-1-activated osteomacs in bone regeneration. Other molecules that modulate inflammatory processes, such as sphingosine 1-phosphate (S1P) ([@B71]), might modulate macrophage actions during bone repair. Indeed, enhanced bone regeneration using biodegradable polymer scaffolds that deliver S1P receptor-targeted drugs has been observed in cranial defects ([@B19]).

Collectively, these data highlight osteomacs as a novel target in bone physiopathology and suggest that factors involved in their regulation might be a future alternative to broaden the spectrum for osteoporosis treatment and, possibly, for other metabolic bone diseases.

Targeting Macrophages in Inflammatory Diseases: Rheumatoid Arthritis {#s3}
====================================================================

RA is a chronic inflammatory autoimmune disorder that affects synovial joints. Current therapies may decrease symptom severity and delay progression, but RA is not curable yet. Macrophages are the most numerous immune cells found in the RA synovium, where they produce the predominant pro-inflammatory cytokines involved in RA pathogenesis (TNFα, IL-1β, and IL-6), together with chemoattractant factors (CCL2 and IL-8) and metalloproteinases (MMP-3 and MMP-12) ([@B33]). Furthermore, mouse experimental models have confirmed the key role of macrophages in RA pathogenesis ([@B20]). Taking into account the effectiveness of the current RA therapies against the main products of activated pro-inflammatory macrophages (TNFα, IL-1β, and IL-6) and the positive correlation between macrophage numbers and joint erosion ([@B27]), we can strongly identify macrophages as a crucial target for therapeutic intervention ([**Figure 1**](#f1){ref-type="fig"}).
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Due to the plasticity of monocytes and macrophages, pathophysiological stimuli can alter the phenotype and function of resident synovial macrophages as well as induce the migration and differentiation of peripheral monocytes into the synovial joint. Studies in mice and humans suggest that RA synovial macrophages (RA-SM) differentiate from blood monocytes that migrate into the synovium ([@B28]; [@B43]) and express a specific set of markers ([**Table 1**](#T1){ref-type="table"}). Actually, in active RA, there is an increase in the total number of macrophages in the synovial membrane, concomitant with a higher expression of pro-inflammatory markers ([@B65]; [@B47]). Interestingly, healthy synovial macrophages express lower levels of M1-associated markers when compared with RA-SM ([@B65]; [@B47]), but display phenotypic features of M2 anti-inflammatory macrophages ([@B37]) ([**Table 1**](#T1){ref-type="table"}). Besides this, the RA synovial hypoxic milieu could contribute to the M1 macrophage polarization phenotype of RA-SM ([@B30]). Therefore, we can assume that macrophage populations are switched towards a pro-inflammatory phenotype in RA environment, and re-polarization of RA-SM could contribute to restore synovium homeostasis ([**Figure 1**](#f1){ref-type="fig"}). In line with this hypothesis, diverse studies have been performed. Particularly, the therapeutic effect of blocking granulocyte-macrophage colony-stimulating factor (GM-CSF) has been confirmed in both RA mouse models ([@B6]) and in phase I and II clinical trials with RA patients ([@B7]; [@B68]). This cytokine plays a main role in RA since it can be detected in the blood, bone marrow, and synovial fluid of RA patients ([@B70]) and represents a well-known M1 polarization inducer ([@B22]). Notably, it has been shown that RA-SM display a GM-CSF-associated pro-inflammatory profile ([@B47]). Another example of a modulator of macrophage polarization with a positive effect in RA is CP-25, a compound derived from total glucosides of peony, which is widely used for the treatment of RA in China ([@B15]). Thus, there is a correlation between the improvement in RA pathology and a polarization switch towards an M2 anti-inflammatory phenotype. However, the specific activation mechanisms of synovial macrophages remain to be elucidated.

###### 

Phenotypic markers of specific macrophage subpopulations in different pathologies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Macrophage subpopulations                                             Markers
  --------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  **Osteomacs**                                                         F4/80^+^, CD115^+^, Mac-3^+^, CD68^+^, Mac-2/galectin-3^low^, TRAP^low1,2^

  **Rheumatoid arthritis-synovial macrophages (RA-SM) and monocytes**   CD50^high^, CD36^high^, MMP12^high^, CCR2^high^, PHD3^high^ (human)CD209^low^, Folate Receptor-^ßlow^(human)^3^

  **Glioma-associated macrophages and microglia (GAMMs)**               Iba1^+^, CD11b^+^, CX3CR1^+^, CCR2^−^, Sall1^+^, CD45^low\ 4^ \[microglia\] CD11b^+^, CD45^high^, MHCII^high^, CCR2^+5^\
                                                                        \[monocyte-derived macrophages\]

  **Tumor-associated macrophages (TAMs)**                               LY6C^+^, MHC-II^+^, CX3CR1^+^, CCR2^+^, I-selectin^+^, TIE2^+6-8^\
                                                                        CD14^+^, CD312^+^, CD115^+^, CD16^+^ (human)

  **Metastasis-associated macrophages (MAMs)**                          F4/80^+^, CD11b^+^, VEGFR^high^, CCR2^high^ CD11c-^low^ ^6--9^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table shows macrophage markers in mice, unless otherwise noted. ^1^ [@B2] ^2^ [@B14] ^3^ [@B47] ^4^ [@B10] ^5^ [@B60] ^6^ [@B21] ^7^ [@B50] ^8^ [@B59] ^9^ [@B56]

Since macrophages are natural phagocytes, a promising future approach is the use of extracellular vesicles (EVs), cell-derived membranous structures that allow intercellular communication. As proof of concept, EVs derived from mesenchymal cells displayed an immunosuppressive effect in RA by inducing an M2 polarization shift ([@B17]; [@B41]). Moreover, EV cargo can be manipulated by packing them with specific proteins or miRNA that could skew macrophages towards a homeostatic phenotype ([@B17]). Altogether, we suggest the modulation of macrophage activation as a promising therapeutic approach for RA ([**Figure 1**](#f1){ref-type="fig"}), but first, deeper understanding of macrophage phenotypic heterogeneity and function in the synovial joints must be achieved.

Immunotherapeutic Strategies Involving Glioma-Associated Microglia and Macrophages {#s4}
==================================================================================

Glioblastoma (GBM, WHO grade IV) is the most aggressive primary brain tumor in adults with poor clinical outcomes despite the current standard of care. Macrophages and microglia---resident brain macrophages originated in the yolk sac during embryogenesis and with expression of specific markers ([**Table 1**](#T1){ref-type="table"})---are predominant immune cells in GBM, representing 30--50% of the tumor bulk, which makes them a possible target for treatment ([**Table 1**](#T1){ref-type="table"}). Both M1 and M2 macrophages have been described in GBM, with M2 correlating with increased tumor growth and worse patient outcome ([@B11]). Currently, reprogramming M2 macrophages to anti-tumorigenic M1 is being extensively studied as a strategy for GBM immunotherapy ([**Figure 1**](#f1){ref-type="fig"}).

Blockage of tumor-derived CD47 has been shown to promote M1 polarization, leading to improved tumor phagocytosis ([@B74]; [@B76]). Although anti-VEGF (vascular endothelial growth factor) therapy with bevacizumab failed in GBM patients, its combination with angiopoietin-2 (Ang-2) inhibition led to M2-to-M1 reprogramming in the tumor microenvironment and prolonged survival in glioma-bearing mice ([@B72]). Similarly, anti-CSF-1R (colony-stimulating factor 1 receptor) treatment with Pexidartinib (PLX3397) specifically decreased M2 tumor-promoting macrophages ([@B49]), without benefitting GBM patients ([@B9]). Nonetheless, its combination with IGF-1R (insulin-like growth factor 1 receptor) or PI3K (phosphatidylinositol 3-kinase) blockade has given promising results ([@B52]). Finally, an increased M1/M2 ratio in glioma-associated microglia and macrophages (GAMMs) has been achieved through pharmacological blockade of chemokine receptor CCR5 ([@B39]) or neuropilin-1, an M2-associated cell surface receptor with pro-tumorigenic functions ([@B44]).

So far, classical immunotherapeutic strategies based on immune checkpoint inhibitors have shown limited efficacy in GBM patients. However, oncolytic viruses emerged as promising therapeutics for several types of cancer, not only as lytic agents that kill tumor cells but also as carriers of immunostimulatory molecules that activate durable anti-tumoral immunity. Oncolytic viruses strongly induce IFN-β, one of the key cytokines needed for CD8-mediated tumor rejection, DC maturation, and maintenance of M1 macrophage polarization ([@B73]; [@B54]). Recently, oncolytic herpes simplex virus (oHSV) genetically engineered to produce IL-12 ([@B16]) and to specifically target tumor cells was shown to induce a remarkable improvement in a murine GBM model ([@B1]). Moreover, the triple-combination approach using IL-12-producing oHSV together with anti-CTLA-4 and anti-PD-1 antibodies showed a synergistic effect in inducing M1 polarization in TAMs and microglia, leading to glioma eradication in mice ([@B61]). The anti-tumor effects of immune checkpoint inhibitors are highly dependent on type I interferon and might also be achieved through the activation of STING (stimulator of interferon genes) ([@B67]). In accordance with this, the STING activator alpha-mangostin has the ability to induce M2-to-M1 macrophage repolarization and exert anti-tumor effects ([@B75]).

Metabolic rewiring during microglia and macrophage polarization is currently extensively studied as a target for treatment not only in GBM but also other pathologies in which microglia play critical roles, including neuroinflammatory and neurodegenerative disorders. Although significant challenges remain to be resolved, e.g., the selectivity of such treatment, "metabolic therapeutics" that interfere with key metabolic pathways and modulate macrophage and microglia polarization hold considerable promise for the development of novel combination therapies for GBM. Most likely, the combination of multiple strategies, including metabolites, oncolytic viruses, immunomodulatory cytokines, and checkpoint inhibitors, will need to be clinically explored.

Targeting Metastasis-Associated Macrophages in Cancer {#s5}
=====================================================

Metastasis involves the dissemination of cancer cells from primary tumors into surrounding tissues, causing about 90% of cancer-associated deaths ([@B38]). Metastasis requires multiple steps, including the participation of TAMs from the primary tumor in the metastatic progression ([@B21]). TAMs trigger tumor growth, initiate angiogenesis, are required for tumor cell migration and invasion ([@B51]), and display a specific set of markers ([**Table 1**](#T1){ref-type="table"}).

Interestingly, recent studies have demonstrated the ability of a distinct population of macrophages to promote secondary tumor development. This population of metastasis-associated macrophages (MAMs) differs in its origin compared to TAMs ([@B50]; [@B5]). Resident macrophages are preferentially recruited in primary tumors, generating TAMs, whereas inflammatory macrophages are recruited in metastatic sites, generating MAMs ([@B50]; [@B35]). Moreover, a metastatic site-specific polarization of macrophages has also been reported in intracranial breast cancer metastases ([@B56]). MAMs in dural metastases show a higher antigen-presenting capacity compared to MAMs within parenchymal brain metastases that show a shift towards an M2 state. MAM polarization was directly linked to inflammation-related molecular pathways and expression of cytokines that cancer cells acquire upon site-specific metastasis. These findings are crucial for the development of improved therapies for metastatic disease dependent of MAM phenotypes at different metastatic locations ([@B56]).

Prometastatic changes in organs where metastases later appear have also been described ([@B31]). Such changes induce the formation of "premetastatic niches", favoring the implantation of circulating tumor cells with an organomimetic phenotype, which satisfies the functional requirements of the niche ([@B31]). That is the case in metastatic melanoma, were changes in the lung microenvironment were detected prior to the establishment of the metastasis ([@B32]). In this regard, resident macrophages and the recruitment of bone marrow-derived macrophages (BMDMs) induce an inflammatory environment in metastatic sites favoring tumor cell colonization and recruitment of additional BMDMs. The increased BMDM population triggers protumoral functions, promoting extravasation and survival of metastasizing cancer cells ([@B34]). BMDM-derived MAMs interact with cells like endothelial cells or cancer-associated fibroblasts, enhancing the metastatic potential of cancer cells, i.e., increasing endothelial affinity and permeability, which supports circulating cancer cell adhesion and migration into the tissue ([@B21]). Thus, the cross-communication between tumor cells and cells from the metastatic microenvironment may favor the development of metastatic niches ([@B4]).

In fact, the blockage of these interactions has already been used as a therapeutic strategy. Treatment with neutralizing antibodies against CCL2 secreted from both tumor cells and stromal cells inhibited the recruitment of circulating monocytes and subsequent accumulation of MAMs ([@B50]). In addition, activation of the CCL2--CCR2 axis increases CCL3 secretion from MAMs, resulting in enhanced MAM--cancer cell interaction and prolonged retention of MAMs at the metastases ([@B35]). Moreover, interruption of CCL2 inhibitory treatment led to increased metastases and mortality in four mouse models of metastatic breast cancer ([@B8]) ([**Figure 1**](#f1){ref-type="fig"}).

Other anti-metastatic therapeutic strategies targeting MAMs are based on a cell-permeable peptide derived from caveolin-1. This molecule has already been described as an anti-metastatic regulator of MAMs in a mouse model of lung metastases. In MAMs of this model, Caveolin-1 specifically inhibits vascular endothelial growth factor A/vascular endothelial growth factor receptor 1 (VEGF-A/VEGFR1) signaling and its downstream effectors, matrix metallopeptidase 9 (MMP9) and CSF-1, being critical for metastasis development and progression and not for primary tumor growth ([@B12]). Even though these results seem promising, further investigation is required to better understand how MAMs regulate metastases to develop future MAM-based therapies ([**Figure 1**](#f1){ref-type="fig"}).

Conclusions and Future Directions {#s6}
=================================

Here, we present evidences for macrophage polarization in the context of M1-associated inflammatory diseases, such as RA, and M2-related disorders, like cancer and non-inflammatory pathologies represented by osteoporosis. Moreover, we also include recently identified macrophage populations, MAMs and osteomacs, representative of the plasticity of these cells.

We believe that targeting macrophage polarization might lead to novel intervention strategies.

Current approaches using macrophages as therapies have essentially been developed in preclinical mouse models mainly for AR and cancer uses. Even though some seem promising, a few drawbacks need to be overcome to ensure a successful implementation. First, neither murine macrophage nor monocyte-derived macrophages fully represent what occurs in human macrophages during homeostasis or disease. Novel human induced pluripotent stem cell (IPCS)-derived macrophage models have been reported and might contribute to a better knowledge of macrophage polarization biology. Second, limitations of therapies using macrophage education include the specificity and durability of treatment. Thus, targeting a specific subset of macrophages in a particular tissue and avoiding deleterious side effects or reeducation when therapies are discontinued are major problems that also need to be addressed. In fact, a major problem in these therapies is the pathological consequences of repolarization promoting autoimmune or inflammatory diseases.

Improving our understanding of the basic mechanisms underlying macrophage plasticity and the identification of relevant pathological and physiological macrophage populations, in health and diseases, will lead to the development of new molecular tools to achieve the aforementioned challenges.
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